uk nb100 74460  (Novus Biologicals)

Journal: Experimental eye research

Article Title: Melanopsin in the human and chicken choroid

doi: 10.1016/j.exer.2024.110053

Figure Lengend Snippet: primary antibodies used in this study.

Article Snippet: Melanopsin , OPN4 , rabbit , polyclonal; immunogen affinity purified , 1:200 , Novus Biologicals, Abington, UK (NB100-74460).

Techniques: Affinity Purification

Journal: Molecular Medicine Reports

Article Title: Abnormal differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis

doi: 10.3892/mmr.2017.6266

Figure Lengend Snippet: Densities of (A) Msi1-, (B) Math-1, (C) Neurog3- (D) and NeuroD1-immunoreactive cells in the control, DSS, DSS-G and DSS-Q groups. *P<0.001. DSS, dextran sulfate sodium-induced colitis vehicle-treated group; DSS-G, 3-[(dodecylthiocarbonyl)-methyl]-glutarimide-treated DSS group; DSS-Q, dehydroxymethylepoxyquinomicin-treated DSS group; Msi1, Musashi 1; Neurog3, neurogenin 3; NeuroD1, neurogenic differentiation D1.

Article Snippet: The sections were incubated with the following primary antibodies for 32 min at 37°C: Monoclonal mouse anti-N-terminal of purified chromogranin A (CgA; 1:1,500; cat. no. M869; Dako Denmark A/S, Glostrup, Denmark); polyclonal rabbit anti-residues 5–21 [APQPGLASPDSPHDPCK] of the human, mouse and rat Musashi 1 (Msi1) protein (1:100; cat. no. NB100-1759; R&D Systems Europe, Abingdon, UK); polyclonal rabbit anti-synthetic peptide surrounding amino acid 190 of human Math-1 (1:50; code no. 3658-100; BioVision, Inc., Milpitas, CA, USA); polyclonal rabbit anti-KLH-conjugated synthetic peptide between 40–69 amino acids from the N-terminal region of human Neurog3 (1:50; cat. no. PA5-11893, Thermo Fisher, Oslo, Norway); and polyclonal rabbit anti-recombinant full-length human neurogenic differentiation D1 (NeuroD1; 1:50; cat. no. PA5-47381; Thermo Fisher).

Techniques: Control

Journal: International Journal of Oncology

Article Title: Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo

doi: 10.3892/ijo.32.5.1049

Figure Lengend Snippet: Figure 1. Cellular viability of 5637 and EJ28 BCa cells after transfection with AS-ODNs against SVV, hTERT or VEGF in combination with the NS-K1 control or with each other 72 h after transfection. Data represent means of 5 repetitions with standard deviations. All values are normalised to NS-K1 (100%). Asterisks indicate significant differences compared to NS-K1 + target-specific AS-ODN (**p<0.01, ***p<0.001).

Article Snippet: ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Protein Antibody Unmasking buffer ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– survivin Rabbit polyclonal antibody to survivin 0.01 M citrate buffer pH 6.0 (NB500-201, Novus Biologicals, Littleton, USA) hTERT Telomerase (Catalytic Unit) antibody 0.01 M citrate buffer pH 6.0 (clone 44F12, Novocastra, Newcastle upon Tyne, UK) VEGF Mouse monoclonal (VG1) antibody to VEGF 0.01 M TRIS/0.001 M EDTA buffer pH 8.0 (NB100-664, Novus Biologicals) CD31 Monoclonal mouse anti-human CD31 0.01 M TRIS/0.001 M EDTA buffer pH 9.0 (clone JC70A, Dako, Hamburg, Germany) ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Design and effects of siVEGF865.

Techniques: Transfection, Control

Journal: International Journal of Oncology

Article Title: Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo

doi: 10.3892/ijo.32.5.1049

Figure Lengend Snippet: Figure 2. Cellular viability of 5637 and EJ28 BCa cells after transfection with siRNAs against SVV, hTERT or VEGF in combination with the NS-si control or with each other 72 h after transfection. Data represent means of 5 repetitions with standard deviations. All values are normalised to NS-si (100%). Asterisks indicate significant differences compared to NS-si + target-specific siRNA (*p<0.05, ***p<0.001).

Article Snippet: ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Protein Antibody Unmasking buffer ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– survivin Rabbit polyclonal antibody to survivin 0.01 M citrate buffer pH 6.0 (NB500-201, Novus Biologicals, Littleton, USA) hTERT Telomerase (Catalytic Unit) antibody 0.01 M citrate buffer pH 6.0 (clone 44F12, Novocastra, Newcastle upon Tyne, UK) VEGF Mouse monoclonal (VG1) antibody to VEGF 0.01 M TRIS/0.001 M EDTA buffer pH 8.0 (NB100-664, Novus Biologicals) CD31 Monoclonal mouse anti-human CD31 0.01 M TRIS/0.001 M EDTA buffer pH 9.0 (clone JC70A, Dako, Hamburg, Germany) ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Design and effects of siVEGF865.

Techniques: Transfection, Control